Publications in collaboration with researchers from Fox Chase Cancer Center (1)

2014

  1. Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer

    Clinical Cancer Research, Vol. 20, Núm. 7, pp. 1925-1934